Bausch Health Co. Inc. (NYSE: BHC) reported Q4 revenue for the quarter came in at $2.21 billion versus the consensus estimate of $2.17 billion.

• Fourth-Quarter 2020 Financial Results
  • Revenues of $2.213 Billion
  • GAAP Cash Generated from Operations of $394 Million
  • GAAP Net Loss of $153 Million
  • Adjusted EBITDA (non-GAAP)1 of $911 Million
• Repaid Debt by Approximately $900 Million in 2020 Using Cash Generated From Operations and More Efficient Cash Management
• Business Recovery Is in Progress, and Bausch Health Is Well Positioned for Success in 2021

"Despite unprecedented business challenges resulting from the COVID-19 pandemic, I'm proud that Bausch Health finished the year strong and outperformed the high end of our latest revenue guidance range," said Joseph C. Papa, chairman and CEO, Bausch Health. "During the pandemic-related downturn, we focused our efforts on growing market share for key promoted products, carefully managed our expenses and continued to invest in our pipeline for future growth opportunities. We generated cash from operations of more than $1.1 billion, which helped us to repay approximately $900 million of our debt."

"We are continuing to execute on our business recovery from the pandemic, and we are well positioned to benefit from recovery-related tailwinds and capitalize on our key growth drivers and catalysts in 2021 as we remain focused on how best to unlock value in the Company, including the planned spinoff of Bausch + Lomb," continued Mr. Papa.

For earnings history and earnings-related data on Bausch Health Co. Inc. (BHC) click here.